CPChloé de Puyraimond

Chloé de Puyraimond

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chloé de Puyraimond has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Amandine Baurand

    Université Bourgogne Europe, CHU Dijon Bourgogne, Inserm, CTM UMR1231, Centre de génétique Dijon France

    1 shared publication
  • Apolline Imbard

    Reference Center for Inborn Error of Metabolism, Hôpital Necker‐Enfants Malades, APHP and Université Paris Cité Paris France

    1 shared publication
  • Jean‐François Benoist

    Metabolic Biochemistry, Hôpital Necker‐Enfants Malades, APHP Paris France

    1 shared publication
  • Julian Delanne

    Université Bourgogne Europe, CHU Dijon Bourgogne, Inserm, CTM UMR1231, Centre de génétique Dijon France

    1 shared publication
  • Laurence Faivre

    Université Bourgogne Europe, CHU Dijon Bourgogne, INSERM, CTM UMR1231, équipe GAD, FHU TRANSLAD, Centre de génétique, Centre de référence Anomalies du Développement et Syndromes Malformatifs, Dijon, France

    1 shared publication
  • Manuel Schiff

    Reference Center for Mitochondrial Disorders (CARAMMEL) and Reference Center for Inborn Errors of Metabolism, Department of Pediatrics, Necker‐Enfants‐Malades Hospital, Assistance Publique‐Hôpitaux de Paris, University of Paris‐Cité, MetabERN Paris France

    1 shared publication

Latest Publications

  • Open Access

    Should PNPO Deficiency Be Treated In Utero? Clinical Findings From Prenatal Pyridoxine Therapy

    by Chloé de Puyraimond, Samia Pichard, Muriel Girard, Julian Delanne, Laurence Faivre, Apolline Imbard, Amandine Baurand, Jean‐François Benoist, Philippa B. Mills, Peter T. Clayton, et al.

    Pyridox(am)ine‐5′‐phosphate oxidase (PNPO) deficiency is characterized by early‐onset epileptic encephalopathy refractory to standard antiseizure medications. It is caused by variants in the PNPO gene, resulting in deficient PNPO enzyme activity, which normally converts pyridoxine‐5′‐phosphate and pyridoxamine‐5′‐phosphate (two vitamers of vitamin B6) into the active cofactor, pyridoxal‐5′‐phosphate (PLP). Treatment relies on PLP or pyridoxine in some cases. Long‐term outcomes remain suboptimal. We describe two cases of unrelated children treated with vitamin B6 (pyridoxine) in utero: one with a confirmed prenatal PNPO diagnosis and one at risk due to family history but ultimately unaffected. In utero pyridoxine, combined with early postnatal PLP treatment, allowed excellent seizure control and normal neurodevelopment in the long term. Notably, our first patient, treated from birth, is now 10 years old, representing the oldest reported PNPO‐deficient individual treated from birth. Case 2 highlights the safety of prenatal B6 supplementation even in unaffected fetuses. These observations support prenatal pyridoxine supplementation as a safe and potentially beneficial strategy in at‐risk PNPO pregnancies.